Gas plasma-conditioned ringer’s lactate enhances the cytotoxic activity of cisplatin and gemcitabine in pancreatic cancer in vitro and in ovo

dc.bibliographicCitation.firstPage123eng
dc.bibliographicCitation.issue1eng
dc.bibliographicCitation.journalTitleCancerseng
dc.bibliographicCitation.volume12eng
dc.contributor.authorLiedtke, Kim-Rouven
dc.contributor.authorFreund, Eric
dc.contributor.authorHermes, Maraike
dc.contributor.authorOswald, Stefan
dc.contributor.authorHeidecke, Claus-Dieter
dc.contributor.authorPartecke, Lars-Ivo
dc.contributor.authorBekeschus, Sander
dc.date.accessioned2021-10-19T07:30:13Z
dc.date.available2021-10-19T07:30:13Z
dc.date.issued2020
dc.description.abstractPancreatic cancer is one of the most aggressive tumor entities. Diffuse metastatic infiltration of vessels and the peritoneum restricts curative surgery. Standard chemotherapy protocols include the cytostatic drug gemcitabine with limited efficacy at considerable toxicity. In search of a more effective and less toxic treatment modality, we tested in human pancreatic cancer cells (MiaPaca and PaTuS) a novel combination therapy consisting of cytostatic drugs (gemcitabine or cisplatin) and gas plasma-conditioned Ringer’s lactate that acts via reactive oxygen species. A decrease in metabolic activity and viability, change in morphology, and cell cycle arrest was observed in vitro. The combination treatment was found to be additively toxic. The findings were validated utilizing an in ovo tumor model of solid pancreatic tumors growing on the chorionallantois membrane of fertilized chicken eggs (TUM-CAM). The combination of the drugs (especially cisplatin) with the plasma-conditioned liquid significantly enhanced the anti-cancer effects, resulting in the induction of cell death, cell cycle arrest, and inhibition of cell growth with both of the cell lines tested. In conclusion, our novel combination approach may be a promising new avenue to increase the tolerability and efficacy of locally applied chemotherapeutic in diffuse metastatic peritoneal carcinomatosis of the pancreas. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/7031
dc.identifier.urihttps://doi.org/10.34657/6078
dc.language.isoengeng
dc.publisherBasel : MDPI AGeng
dc.relation.doihttps://doi.org/10.3390/cancers12010123
dc.relation.essn2072-6694
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subject.ddc610eng
dc.subject.otherAnticancer drugseng
dc.subject.otherCombination therapyeng
dc.subject.otherKINPeneng
dc.subject.otherPlasma medicineeng
dc.subject.otherReactive oxygen and nitrogen specieseng
dc.subject.otherROSeng
dc.titleGas plasma-conditioned ringer’s lactate enhances the cytotoxic activity of cisplatin and gemcitabine in pancreatic cancer in vitro and in ovoeng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccesseng
wgl.contributorINPeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cancers-12-00123-v2.pdf
Size:
2.84 MB
Format:
Adobe Portable Document Format
Description:
Collections